These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting fibrosis in systemic sclerosis. Lafyatis R Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):395-400. PubMed ID: 17214585 [TBL] [Abstract][Full Text] [Related]
4. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD). Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M Front Immunol; 2020; 11():1990. PubMed ID: 33013852 [TBL] [Abstract][Full Text] [Related]
5. Role of Alarmins in the Pathogenesis of Systemic Sclerosis. Giovannetti A; Straface E; Rosato E; Casciaro M; Pioggia G; Gangemi S Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679721 [TBL] [Abstract][Full Text] [Related]
6. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795 [TBL] [Abstract][Full Text] [Related]
8. Macrophages as determinants and regulators of fibrosis in systemic sclerosis. Al-Adwi Y; Westra J; van Goor H; Burgess JK; Denton CP; Mulder DJ Rheumatology (Oxford); 2023 Feb; 62(2):535-545. PubMed ID: 35861385 [TBL] [Abstract][Full Text] [Related]
9. Current Concepts on the Pathogenesis of Systemic Sclerosis. Truchetet ME; Brembilla NC; Chizzolini C Clin Rev Allergy Immunol; 2023 Jun; 64(3):262-283. PubMed ID: 34487318 [TBL] [Abstract][Full Text] [Related]
10. The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting. Romano E; Rosa I; Fioretto BS; Matucci-Cerinic M; Manetti M Curr Mol Med; 2022; 22(3):209-239. PubMed ID: 33823766 [TBL] [Abstract][Full Text] [Related]
11. The Kavian N; Mehlal S; Jeljeli M; Saidu NEB; Nicco C; Cerles O; Chouzenoux S; Cauvet A; Camus C; Ait-Djoudi M; Chéreau C; Kerdine-Römer S; Allanore Y; Batteux F Front Immunol; 2018; 9():1896. PubMed ID: 30177933 [TBL] [Abstract][Full Text] [Related]
12. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Fuschiotti P; Medsger TA; Morel PA Arthritis Rheum; 2009 Apr; 60(4):1119-28. PubMed ID: 19333920 [TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cells for systemic sclerosis treatment. Farge D; Loisel S; Lansiaux P; Tarte K Autoimmun Rev; 2021 Mar; 20(3):102755. PubMed ID: 33476823 [TBL] [Abstract][Full Text] [Related]
14. A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis. Manetti M; Rosa I; Messerini L; Guiducci S; Matucci-Cerinic M; Ibba-Manneschi L J Cell Mol Med; 2014 Feb; 18(2):253-62. PubMed ID: 24467430 [TBL] [Abstract][Full Text] [Related]
15. Novel insights on the role of the innate immune system in systemic sclerosis. York MR Expert Rev Clin Immunol; 2011 Jul; 7(4):481-9. PubMed ID: 21790291 [TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. Jerjen R; Nikpour M; Krieg T; Denton CP; Saracino AM J Am Acad Dermatol; 2022 Nov; 87(5):937-954. PubMed ID: 35131402 [TBL] [Abstract][Full Text] [Related]
17. Involvement of Disabled-2 on skin fibrosis in systemic sclerosis. Mei X; Zhao H; Huang Y; Tang Y; Shi X; Pu W; Jiang S; Ma Y; Zhang Y; Bai L; Tu W; Zhao Y; Jin L; Wu W; Wang J; Liu Q J Dermatol Sci; 2020 Jul; 99(1):44-52. PubMed ID: 32571632 [TBL] [Abstract][Full Text] [Related]
19. Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion. Servaas NH; Mariotti B; van der Kroef M; Wichers CGK; Pandit A; Bazzoni F; Radstake TRDJ; Rossato M Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922041 [TBL] [Abstract][Full Text] [Related]